{"id":1367,"date":"2026-04-03T15:00:00","date_gmt":"2026-04-03T15:00:00","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/?p=1367"},"modified":"2026-03-19T19:57:33","modified_gmt":"2026-03-19T19:57:33","slug":"selank-peptide-anxiolytic-bdnf-research-guide","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/","title":{"rendered":"Selank Peptide: Anxiolytic Research, BDNF Modulation &#038; Nootropic Applications"},"content":{"rendered":"<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<p>Selank started as an immunology project. A group at the Institute of Molecular Genetics in Moscow took tuftsin \u2014 a naturally occurring immune peptide your body makes from immunoglobulin G \u2014 and bolted three extra amino acids onto the end. The goal was better metabolic stability. What they got was a heptapeptide that crosses into neuroscience territory in ways nobody predicted.<\/p>\n\n<p>Anxiolytic effects comparable to benzodiazepines. No sedation. No amnesia. No dependence. Plus BDNF modulation, enkephalinase inhibition, and immunomodulatory activity all wrapped into seven amino acids. <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank<\/a> (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is one of those compounds where the mechanism of action section reads like it&#8217;s describing four different drugs. But it&#8217;s one peptide. And the preclinical data is surprisingly consistent.<\/p>\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#What_Is_Selank_Chemical_Identity\" >What Is Selank? Chemical Identity<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Development_History\" >Development History<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Mechanism_of_Action_Five_Pathways_From_One_Peptide\" >Mechanism of Action: Five Pathways From One Peptide<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Preclinical_Results\" >Preclinical Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Safety_Profile\" >Safety Profile<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Regulatory_Status\" >Regulatory Status<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Availability\" >Availability<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#Conclusion\" >Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/selank-peptide-anxiolytic-bdnf-research-guide\/#References\" >References<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"What_Is_Selank_Chemical_Identity\"><\/span>What Is Selank? Chemical Identity<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Seven amino acids. TKPRPGP. A synthetic regulatory peptide from the tuftsin family.<\/p>\n\n<ul>\n<li><strong>Sequence:<\/strong> Thr-Lys-Pro-Arg-Pro-Gly-Pro<\/li>\n<li><strong>Molecular Formula:<\/strong> C<sub>33<\/sub>H<sub>57<\/sub>N<sub>11<\/sub>O<sub>9<\/sub><\/li>\n<li><strong>Molecular Weight:<\/strong> 751.87 g\/mol<\/li>\n<li><strong>CAS Number:<\/strong> 129954-34-3<\/li>\n<li><strong>Classification:<\/strong> Synthetic heptapeptide, tuftsin analogue<\/li>\n<li><strong>Solubility:<\/strong> Freely water-soluble<\/li>\n<\/ul>\n\n<p>The first four residues (Thr-Lys-Pro-Arg) are tuftsin \u2014 a tetrapeptide that the spleen cleaves from IgG&#8217;s Fc region. It&#8217;s a well-characterized immune activator: phagocyte stimulation, cell motility, immune cell function. Adding Pro-Gly-Pro onto the C-terminus did two things. It slowed enzymatic degradation \u2014 extending the compound&#8217;s active window well beyond what native tuftsin achieves \u2014 and it introduced neurotropic properties that the parent peptide simply doesn&#8217;t have.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Development_History\"><\/span>Development History<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Late 1990s, early 2000s. Nikolai Myasoedov&#8217;s lab at the Institute of Molecular Genetics, Russian Academy of Sciences. The idea: make a tuftsin analogue that&#8217;s harder for enzymes to chew apart, keep the immunomodulatory profile, and see what else happens.<\/p>\n\n<p>What else happened was anxiolytic activity. Strong enough that a 0.15% intranasal formulation eventually got registered by the Russian Federation Ministry of Health for generalized anxiety disorder and neurasthenic conditions. That makes Selank one of a handful of peptides anywhere in the world with actual regulatory approval as an anxiolytic agent \u2014 though it&#8217;s still unapproved by the FDA and EMA, and classified as a research compound in most countries.<\/p>\n\n<p>Selank&#8217;s sibling compound is <a href=\"https:\/\/lotilabs.com\/product\/semax-5mg\/\">Semax<\/a> \u2014 an ACTH<sub>4-10<\/sub> analogue from the same institute, primarily known for neuroprotection and cognition. Both inhibit enkephalin-degrading enzymes. Different core structures, overlapping but distinct downstream effects.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_Five_Pathways_From_One_Peptide\"><\/span>Mechanism of Action: Five Pathways From One Peptide<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>This is where Selank gets unusual. Most anxiolytics work through one receptor system. Selank hits at least five distinct molecular pathways. That&#8217;s not hand-waving \u2014 each one has published data behind it.<\/p>\n\n<h3>1. GABA<sub>A<\/sub> Receptor Modulation (Without the Benzo Baggage)<\/h3>\n\n<p>Volkova&#8217;s group showed that Selank alters GABA binding at its receptors without competing for the agonist site. Allosteric modulation \u2014 changing how the receptor responds to GABA rather than mimicking GABA directly. That&#8217;s the same general category as benzodiazepines, but the details matter enormously.<\/p>\n\n<p>Kasian et al. (PMID: 26847159) went deeper with a transcriptomic study \u2014 84 genes related to neurotransmission, comparing Selank vs. GABA administration. Strong positive correlation in gene expression changes. Selank isn&#8217;t just tweaking receptor binding; it&#8217;s shifting the entire GABAergic transcription program.<\/p>\n\n<p>And yet \u2014 no sedation. No amnesia. No muscle relaxation. No dependence. In head-to-head comparisons with medazepam (a benzodiazepine), Selank matched anxiolytic efficacy while producing none of the signature benzodiazepine side effects (Seredenin et al., 1998). That separation of anxiolysis from sedation is rare. And pharmacologically interesting.<\/p>\n\n<h3>2. BDNF and NGF: Neurotrophin Regulation<\/h3>\n\n<p>This might be Selank&#8217;s most important mechanism for neuroscience researchers. Inozemtseva et al. found that Selank rapidly boosts BDNF mRNA in the rat hippocampus \u2014 transcript levels climb within hours. The protein curve is more complex: a transient dip followed by a sustained rise above baseline. Rapid signaling cascade first, then slower genomic effects that build over time.<\/p>\n\n<p>Even more interesting: Kolik et al. (PMID: 31625062) showed that Selank doesn&#8217;t just raise BDNF blindly. In rats exposed to ethanol, where BDNF gets pathologically elevated in hippocampus and frontal cortex, Selank <em>prevented<\/em> that increase while simultaneously improving cognitive performance. State-dependent modulation. The compound normalizes BDNF toward physiological levels rather than simply cranking it up \u2014 and that distinction matters for anyone studying the neurotrophin hypothesis of affective disorders.<\/p>\n\n<p>For researchers working with <a href=\"https:\/\/lotilabs.com\/resources\/delta-sleep-inducing-peptide-dsip-benefits-uses-and-dosage\/\">other regulatory neuropeptides like DSIP<\/a>, Selank&#8217;s neurotrophin-centric mechanism opens complementary research angles.<\/p>\n\n<h3>3. Enkephalinase Inhibition<\/h3>\n\n<p>Zozulya et al. measured this directly. Selank inhibits the enzymes that break down enkephalins in plasma \u2014 and it does so more potently than bacitracin and puromycin, two established peptidase inhibitors. Since enkephalins get torn apart by aminopeptidases, NEP, and ACE within seconds of release, even modest inhibition of those enzymes meaningfully extends how long enkephalins survive to interact with opioid receptors.<\/p>\n\n<p>But Selank itself doesn&#8217;t bind opioid receptors. Meshavkin et al. confirmed this: naloxone blocks Selank&#8217;s behavioral effects (indicating opioid system involvement), yet the peptide shows zero competition at \u03b4 or \u03bc receptor binding sites. Indirect engagement. Selank protects the enkephalins your body is already making instead of replacing them. That&#8217;s a subtle but critical pharmacological distinction.<\/p>\n\n<h3>4. Serotonin and Dopamine<\/h3>\n\n<p>Nadorova et al. found Selank&#8217;s serotonergic effects are state-dependent. Normal baseline conditions? Not much change in 5-HT or 5-HIAA. But when serotonin is pathologically elevated? Selank normalizes accumulation in frontal cortex, hypothalamus, and amygdala. It&#8217;s a modulator, not a simple up- or down-regulator.<\/p>\n\n<p>On the dopamine side, that same Kasian transcriptomic study (PMID: 26847159) caught something specific: Selank activates <em>Drd5<\/em> gene expression \u2014 dopamine receptor D5. That receptor plays directly into long-term potentiation, memory consolidation, and learning. Molecular basis for the nootropic effects that behavioral testing has been documenting.<\/p>\n\n<h3>5. Immunomodulation (The Tuftsin Legacy)<\/h3>\n\n<p>Selank didn&#8217;t forget where it came from. IL-6 modulation, Th1\/Th2 cytokine balance shifts \u2014 both documented in research models of generalized anxiety with neurasthenic features. Fourteen days of Selank produced transient IL-6 bumps and cytokine ratio changes suggesting the compound touches both pro- and anti-inflammatory signaling.<\/p>\n\n<p>That neuroimmune crossover is what makes Selank unique among anxiolytic research compounds. Most anxiety drugs don&#8217;t touch the immune system. Selank bridges both worlds \u2014 which matters increasingly as the link between immune dysregulation and anxiety-like behaviors gets more research attention.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Preclinical_Results\"><\/span>Preclinical Results<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h3>Anxiety Models<\/h3>\n\n<p>Kozlovskaya et al. (2003): 300 \u03bcg\/kg in rats. Peripheral activity increased 63.4%. Vertical activity up 10.2%. Hole investigations up 23.0%. That&#8217;s reduced anxiety with enhanced exploration \u2014 an activating profile, not a sedating one. Benzodiazepines typically suppress exploration while reducing anxiety. Selank does the opposite.<\/p>\n\n<p>Semenova et al. (2010) extended this across species: reduced aggression and fear responses in multiple animal models. Not just one paradigm. Broad-spectrum anxiolysis.<\/p>\n\n<h3>Cognition<\/h3>\n\n<p>Object recognition testing at 0.3 mg\/kg: cognitive enhancement in aged rats. In alcohol withdrawal models, Selank prevented the memory and attention disruptions that normally accompany ethanol cessation (PMID: 31625062). Simultaneous anxiolytic and nootropic effects \u2014 both driven, apparently, by BDNF modulation and D5 receptor activation.<\/p>\n\n<h3>Versus Benzodiazepines<\/h3>\n\n<p>The head-to-head data against medazepam tells the story clearly:<\/p>\n\n<ul>\n<li>Anxiolytic efficacy: equivalent<\/li>\n<li>Sedation: absent with Selank (may relate to its upregulation of hypocretin\/Hcrt gene expression \u2014 a wakefulness signal)<\/li>\n<li>Amnesia: absent. Selank actually <em>enhances<\/em> memory<\/li>\n<li>Dependence and withdrawal: none observed in any preclinical model<\/li>\n<\/ul>\n\n<p>For investigators studying <a href=\"https:\/\/lotilabs.com\/resources\/the-benefits-of-pinealon-peptide-for-brain-and-longevity-research\/\">CNS-active regulatory peptides<\/a>, that&#8217;s about as clean a comparison as you&#8217;ll find.<\/p>\n\n<h3>Alcohol Withdrawal<\/h3>\n\n<p>Chronic ethanol exposure followed by abrupt cessation. Selank reduced withdrawal-associated anxiety and cognitive disruption on social interaction and maze tasks. Consistent with the compound&#8217;s known effects on enkephalin preservation, BDNF normalization, and GABAergic tone. Multiple mechanisms converging on the same withdrawal phenotype.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Safety_Profile\"><\/span>Safety Profile<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>What the preclinical and domestic data show:<\/p>\n\n<ul>\n<li><strong>No sedation or cognitive impairment<\/strong> \u2014 the opposite of benzodiazepine-class effects<\/li>\n<li><strong>No dependence.<\/strong> No withdrawal. Not even a hint in animal models<\/li>\n<li><strong>No antibody formation<\/strong> \u2014 immunogenicity testing came back clean<\/li>\n<li><strong>Fast clearance:<\/strong> metabolized in the liver, excreted renally. Gone from circulation in about 10 minutes. Low accumulation risk<\/li>\n<\/ul>\n\n<p>Important caveat: most published safety data comes from Russian research institutions. Independent international replication is limited. Researchers should weigh that when designing protocols and interpreting findings.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Regulatory_Status\"><\/span>Regulatory Status<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><strong>Russia:<\/strong> Approved. 0.15% intranasal formulation for generalized anxiety and neurasthenia. One of the few peptide anxiolytics with any regulatory approval worldwide.<\/p>\n\n<p><strong>United States:<\/strong> Not FDA-approved. Research compound only. Not available for compounding under current guidance.<\/p>\n\n<p><strong>EU\/International:<\/strong> Not EMA-approved. Generally classified as a research compound.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Availability\"><\/span>Availability<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Loti Labs carries <a href=\"https:\/\/lotilabs.com\/product\/selank-10mg\/\">Selank 10mg<\/a> ($49.99) \u2014 lyophilized, \u226598% purity, third-party HPLC and mass spec verified. For researchers running parallel neuropeptide studies, <a href=\"https:\/\/lotilabs.com\/product\/semax-5mg\/\">Semax 5mg<\/a> ($39.99) \u2014 the related ACTH<sub>4-10<\/sub> analogue with overlapping enkephalinase inhibition and its own neuroprotective profile \u2014 is available as well.<\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span>Conclusion<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>A tuftsin analogue that became an anxiolytic. GABAergic modulation without benzodiazepine side effects. BDNF regulation that normalizes rather than just elevates. Enkephalinase inhibition that preserves endogenous opioid signaling without touching opioid receptors directly. Serotonin and dopamine modulation. Immunomodulatory activity.<\/p>\n\n<p>Five pathways from seven amino acids. That&#8217;s not a typical pharmacological profile \u2014 and it&#8217;s exactly why Selank keeps attracting new research interest from labs studying anxiety, cognition, neuroplasticity, and the neuroimmune interface.<\/p>\n\n<p><em>For laboratory and research use only. Not for human consumption.<\/em><\/p>\n\n<h2><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<ol>\n<li>Kasian A, Kolomin T, Andreeva L, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. <em>Front Pharmacol.<\/em> 2017;8:782. PMID: 26847159<\/li>\n<li>Kolik LG, Nadorova AV, Antipova TA, et al. Selank, peptide analogue of tuftsin, protects against ethanol-induced memory impairment by regulating of BDNF content in the hippocampus and prefrontal cortex in rats. <em>Bull Exp Biol Med.<\/em> 2019;167(5):641-644. PMID: 31625062<\/li>\n<li>Zozulya AA, Kost NV, Sokolov OY, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. <em>Bull Exp Biol Med.<\/em> 2001;131(4):315-317.<\/li>\n<li>Meshavkin VK, Kost NV, Sokolov OY, et al. Selank action on opioid system is mediated by enkephalinase inhibition. <em>Bull Exp Biol Med.<\/em> 2006;142(5):575-577.<\/li>\n<li>Seredenin SB, Kozlovskaya MM, Blednov YA, et al. The anxiolytic action of an analog of the endogenous peptide tuftsin on the model of &#8220;anxiety&#8221; in mice. <em>Zh Vyssh Nerv Deiat Im I P Pavlova.<\/em> 1998;48(1):153-160.<\/li>\n<li>Kozlovskaya MM, Kozlovskii II, Val&#8217;dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. <em>Neurosci Behav Physiol.<\/em> 2003;33(9):853-860.<\/li>\n<li>Seredenin SB, Blednov YA, Badyshtov BA, et al. Effect of Selank on neurasthenia and generalized anxiety disorder. <em>Zh Nevrol Psikhiatr Im S S Korsakova.<\/em> 2008;108(4):38-48. PMID: 18454096<\/li>\n<li>Uchakina ON, Uchakin PN, et al. Immunomodulatory effects of Selank in subjects with anxiety-asthenic disorders. <em>Zh Nevrol Psikhiatr Im S S Korsakova.<\/em> 2008;108(5):71-75.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Research guide on Selank, a synthetic heptapeptide with anxiolytic effects comparable to benzodiazepines without sedation. Covers BDNF modulation, enkephalinase inhibition, and immunomodulatory mechanisms.<\/p>\n","protected":false},"author":1,"featured_media":1384,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-1367","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-peptides"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1367","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1367"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1367\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/1384"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1367"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1367"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1367"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}